These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 8537178

  • 1. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
    Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY.
    Int J Pept Protein Res; 1995; 46(3-4):244-52. PubMed ID: 8537178
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C.
    J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
    [Abstract] [Full Text] [Related]

  • 5. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M, Cheng LL, Stoev S, Bankowski K, Przybyiski J, Klis WA, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1995 Oct; 1(1):66-79. PubMed ID: 9222985
    [Abstract] [Full Text] [Related]

  • 6. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
    Manning M, Kruszynski M, Bankowski K, Olma A, Lammek B, Cheng LL, Klis WA, Seto J, Haldar J, Sawyer WH.
    J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY, Wo NC, Cheng LL, Manning M.
    J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
    [Abstract] [Full Text] [Related]

  • 9. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
    Manning M, Misicka A, Olma A, Klis WA, Bankowski K, Nawrocka E, Kruszynski M, Kolodziejczyk A, Cheng LL, Seto J.
    J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
    [Abstract] [Full Text] [Related]

  • 10. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays.
    Chan WY, Wo NC, Stoev ST, Cheng LL, Manning M.
    Exp Physiol; 2000 Mar; 85 Spec No():7S-18S. PubMed ID: 10795902
    [Abstract] [Full Text] [Related]

  • 11. Novel approach to the design of synthetic radioiodinated linear V1A receptor antagonists of vasopressin.
    Manning M, Bankowski K, Barberis C, Jard S, Elands J, Chan WY.
    Int J Pept Protein Res; 1992 Mar; 40(3-4):261-7. PubMed ID: 1478783
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M, Stoev S, Bankowski K, Misicka A, Lammek B, Wo NC, Sawyer WH.
    J Med Chem; 1992 Jan 24; 35(2):382-8. PubMed ID: 1531076
    [Abstract] [Full Text] [Related]

  • 13. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S, Cheng LL, Olma A, Klis WA, Manning M, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1999 Mar 24; 5(3):141-53. PubMed ID: 10323558
    [Abstract] [Full Text] [Related]

  • 14. Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.
    Manning M, Stoev S, Kolodziejczyk A, Klis WA, Kruszynski M, Misicka A, Olma A, Wo NC, Sawyer WH.
    J Med Chem; 1990 Nov 24; 33(11):3079-86. PubMed ID: 2231609
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Design of potent oxytocin antagonists featuring D-tryptophan at position 2.
    Flouret G, Brieher W, Mahan K, Wilson L.
    J Med Chem; 1991 Feb 24; 34(2):642-6. PubMed ID: 1995888
    [Abstract] [Full Text] [Related]

  • 18. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
    Manning M, Olma A, Klis WA, Seto J, Sawyer WH.
    J Med Chem; 1983 Nov 24; 26(11):1607-13. PubMed ID: 6631916
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
    Manning M, Stoev S, Cheng LL, Wo NC, Chan WY.
    J Pept Sci; 1999 Nov 24; 5(11):472-90. PubMed ID: 10587312
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.